SGLT2 Inhibitors and External Genital Infection in Male Patients With Type 2 Diabetes

Among adults with type 2 diabetes (T2D), is the use of sodium-glucose cotransporter 2 inhibitors (SGLT2Is) associated with higher risk of male external genital infection (MEGI) than glucagon-like peptide-1 receptor agonists (GLP-1RAs)?In this cohort study with 239 757 participants, initiation of SGLT2Is was associated with a higher risk of MEGI compared with initiation of GLP-1RAs in patients with T2D. The increased risk of MEGI with the use of SGLT2Is was observed across different subgroup analyses.These findings suggest that patients with T2D newly receiving SGLT2Is are at a higher risk of MEGI compared with those receiving GLP-1RAs, and clinicians should be cautious when prescribing SGLT2Is to male patients with T2D.

Corresponding Authors: Kuan-Yu Wu, MD (hn85386039@gmail.com); and Che-Yuan Hu, MD, PhD (greatoldhu@gmail.com); Department of Urology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, No. 138, Sheng Li Road, Tainan, Taiwan.

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.